• Nenhum resultado encontrado

[PDF] Top 20 Rev. Bras. Hematol. Hemoter. vol.33 número2

Has 10000 "Rev. Bras. Hematol. Hemoter. vol.33 número2" found on our website. Below are the top 20 most common "Rev. Bras. Hematol. Hemoter. vol.33 número2".

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... As a result, the first issue of volume 33 has a more elaborate layout, but even more importantly, it was more painstakingly checked to improve the content and overall quality. On observing the profile of the ... See full document

3

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... Rev Bras Hematol Hemoter.[r] ... See full document

1

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... Hydroxyurea is a commonly used medication because it has the ability to raise levels of fetal hemoglobin, decrease the frequency of vaso-occlusive episodes and thus improve the clinical [r] ... See full document

5

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... (1) Acid phosphatase staining was performed in blood smears of Phrynops geoffroanus using the lead phosphate method, (2) with eosinophils being strongly stained (Figure 1)1. In human [r] ... See full document

1

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... In conclusion, no significant variations were seen in the platelet indices that would suggest the existence of effects related to hypertension or diabetes mellitus or any consequences ar[r] ... See full document

2

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... Other important remarks are: there is no medical follow up of this treatment in the Brazilian population; patients can decide the quantity of foods (and of these nutrients) that they wan[r] ... See full document

6

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... The differential morphological diagnosis of histiocytic sarcoma includes inflammatory pseudotumor, follicular dendritic cell sarcoma, interdigitating dendritic cell sarcoma, malignant La[r] ... See full document

3

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... Velocardiofacial syndrome patients with a heterozygous chromosome 22q11 deletion have giant platelets. Lazier K, Chow EW, AbdelMalik P, Scutt LE, Weksbergs R, Bassett AS[r] ... See full document

4

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... Whole-body positron emission tomography using 18F- fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic v[r] ... See full document

8

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median [r] ... See full document

9

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... 33. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA, Boudreau C, Nelson G, Oudshoorn M, van Rood J, Velardi A, Maiers M, Setterholm M, Confer D, Posch PE, Anasetti C, Kamani N, Miller JS, ... See full document

5

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... Results: The prevalence and incidence rates per 100,000 inhabitants in the period of six months were, respectively: acute myeloid leukemia 1.5 and 0.7; acute lymphoblastic leukemia 0.5 [r] ... See full document

6

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... After characterizing the sociodemographic profile of sickle cell disease patients registered in the Rio de Janeiro State Coordinating Blood Bank in the period of 2002-2008, a retrospecti[r] ... See full document

5

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... The results of aggregation with collagen were considered normal on the first day, with a progressive decrease in platelet function during the five days, when the aggregation was consider[r] ... See full document

5

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... Disease progression after R-CHOP treatment associated with the loss of CD20 antigen expression.. Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Instituto Octa[r] ... See full document

3

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... In Brazil, population-based information is available on anemia in under 5-year- old children; however, data on this problem and associated factors in hospitalized children are scarce.. T[r] ... See full document

5

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... 4. Vichinsky EP. Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Semin Hematol. 1991;28(3):220-6. 5. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention ... See full document

2

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... To reach this conclusion, however, would require the authors to have taken into account that it is possible that, in fact, the association found might reflect an underlying association n[r] ... See full document

3

Rev. Bras. Hematol. Hemoter.  vol.33 número2

Rev. Bras. Hematol. Hemoter. vol.33 número2

... The results of this study also showed that the prevalence of anemia was significantly higher in the presence of an acute phase response as this reduces serum iron concentrations thereby [r] ... See full document

4

Rev. Bras. Hematol. Hemoter.  vol.33 número6

Rev. Bras. Hematol. Hemoter. vol.33 número6

... Jesús M Hernández-Rivas Secondary myeloid neoplasias are a heterogeneous group of diseases characterized by the proliferation of myeloid cells; they were recently recognized by the World[r] ... See full document

2

Show all 10000 documents...